Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, announces the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA therapeutic design, manufacturing, and validation. Terrain Bio has developed advanced machine learning models for RNA sequence optimization and active learning workflows, alongside a best-in-class R&D-scale mRNA manufacturing platform, to connect computational design directly with experimental feedback.
Read the full article: Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics //
Source: https://www.businesswire.com/news/home/20260116638047/en/Eclipsebio-Acquires-Terrain-Bio-to-Expand-Its-End-to-End-AI-Platform-for-the-Design-Manufacturing-and-Validation-of-RNA-Therapeutics